高级检索
当前位置: 首页 > 详情页

Knockdown of PGBD5 inhibits the malignant progression of glioma through upregulation of the PPAR pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Yunnan Prov, Dept Neurosurg, 157 Jinbi Rd, Kunming 650500, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Dept Neurosurg, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Med Sch, Kunming 650500, Yunnan, Peoples R China
出处:
ISSN:

关键词: glioma PGBD5 tumor growth PPAR signaling transposons

摘要:
Glioma is the most common type of primary intracranial malignant tumor, and because of its high invasiveness and recurrence, its prognosis remains poor. The present study investigated the biological function of piggyBac transportable element derived 5 (PGBD5) in glioma. Glioma and para-cancerous tissues were obtained from five patients. Reverse transcription-quantitative PCR and western blotting were used to detect the expression levels of PGBD5. Transwell assay and flow cytometry were used to evaluate cell migration, invasion, apoptosis and cell cycle distribution. In addition, a nude mouse tumor transplantation model was established to study the downstream pathways of PGBD5 and the molecular mechanism was analyzed using transcriptome sequencing. The mRNA and protein expression levels of PGBD5 were increased in glioma tissues and cells. Notably, knockdown of PGBD5 in vitro could inhibit the migration and invasion of glioma cells. In addition, the knockdown of PGBD5 expression promoted apoptosis and caused cell cycle arrest in the G2/M phase, thus inhibiting cell proliferation. Furthermore, in vivo experiments revealed that knockdown of PGBD5 expression could inhibit Ki67 expression and slow tumor growth. Changes in PGBD5 expression were also shown to be closely related to the peroxisome proliferator-activated receptor (PPAR) signaling pathway. In conclusion, interference with PGBD5 could inhibit the malignant progression of glioma through the PPAR pathway, suggesting that PGBD5 may be a potential molecular target of glioma.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]First Peoples Hosp Yunnan Prov, Dept Neurosurg, 157 Jinbi Rd, Kunming 650500, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Dept Neurosurg, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Med Sch, Kunming 650500, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]First Peoples Hosp Yunnan Prov, Dept Neurosurg, 157 Jinbi Rd, Kunming 650500, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Dept Neurosurg, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China [3]Kunming Univ Sci & Technol, Med Sch, Kunming 650500, Yunnan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:87984 今日访问量:0 总访问量:732 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号